Literature DB >> 1760907

Barium meal or endoscopy? A prospective randomized study of patient preference and physician decision making.

G W Stevenson1, G Norman, R Frost, S Somers.   

Abstract

This study examines the preference of 64 out-patients for either a barium meal or an upper gastrointestinal endoscopy. The sequence of the examinations was randomized to avoid order bias. An initial preference for a barium meal of almost two-to-one, with 53% having no preference, was changed after the investigations to a preference for endoscopy of two-to-one with 5% having no preference. The use of mild sedation and the skill of the endoscopist had a major impact on the patients' opinion of the endoscopic procedure, and on their choice of examination for any repeat study. There was little agreement between clinical diagnosis and the result of investigation, but clinicians tended to accept the reported result of the investigation, especially if the result was abnormal. Despite a change in diagnosis in 34 of 49 patients there was little change in management as a result of the investigations, supporting the view that young patients with dyspepsia may be managed with symptomatic treatment initially, and without investigation. This study lends further support to the view that endoscopy should be the investigation of choice in patients with persistent dyspepsia, especially those whose age or infirmity may make barium examination suboptimal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1760907     DOI: 10.1016/s0009-9260(05)81266-8

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  2 in total

1.  Dyspepsia: is a trial of therapy appropriate?

Authors:  W G Thompson
Journal:  CMAJ       Date:  1995-08-01       Impact factor: 8.262

2.  Patient attitudes to myelography, computed tomography and magnetic resonance imaging when examined for suspected lumbar disc herniation.

Authors:  M J Albeck; B Danneskiold-Samsøe
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.